Managing the neuropsychiatric symptoms of Parkinson's disease.
Neuropsychiatric symptoms frequently complicate the treatment of Parkinson's disease (PD). Approximately 27% of PD patients are demented, and approximately 19% are cognitively impaired without being demented. These 46% of patients are prone to development of delirium when they take antiparkinsonian drugs. Approximately 40% of PD patients are depressed. The depression may be endogenous or exogenous, apathetic or agitated. Approximately 40% of PD patients are anxious or have panic attacks. The attacks may or may not be associated with depression. This article reviews the diagnosis of these symptoms and discusses their management.
Lieberman
A
A
Muhammad Ali Parkinson Research Center at Barrow Neurological Institute, Phoenix, AZ 85103, USA.
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006801:Humans; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000009:adverse effects
D000978:Antiparkinson Agents; D011619:Psychotropic Drugs